Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 30, 2009

Optimata and Teva to Repurpose Shelved Cancer Drug Candidates

  • Optimata entered a collaboration with Teva Pharmaceutical to develop candidates for solid tumor cancers. The partners will select compounds that had been previously discontinued in development to re-evaluate.

    Rescue and redirection of the program will be done using Optimata’s predictive biosimulation technology. Optimata Virtual Patient® comprises computer-implemented mathematical algorithms of key physiological, pathological, and pharmacological processes in the body of the patient.

    It then unfolds drug-patient dynamic interactions, enabling drug developers to perform virtual clinical trials and clinical indication match for patient population as well as forecast optimal drug treatments for a given trial end point, according to the companies. Moreover, calibrated with patient-specific parameters, Optimata’s technology can tailor improved treatments of various monotherapies and combination therapies of targeted drugs and chemotherapeutics, they add.

    Optimata will receive up-front payments, development milestones, and royalties. Separately, Teva Pharmaceutical made an undisclosed equity investment in Optimata.

Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »